Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Bayer Cropscience Limited's net profit margin of 10.7% in FY2025 reflects moderate profitability, with operating margin at 11.4% and gross margin at 36.0%.
In FY 2025, Bayer Cropscience Limited posted a gross margin of 36.0%, an operating margin of 11.4%, a net margin of 10.7%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Bayer Cropscience Limited's revenue grew 8.6% to 53.14B in FY2025, but net profit declined 23.3% to 5.68B — indicating margin compression.
In FY 2025, Bayer Cropscience Limited's revenue grew by 8.6% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Bayer Cropscience Limited's ROE of 19.9% in FY2025 indicates good shareholder returns.
In FY 2025, Bayer Cropscience Limited reported an ROE of 19.9%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Bayer Cropscience Limited's FCF/NI ratio of 0.39x in FY2025 indicates weak cash generation raising concerns about earnings quality.
In FY 2025, Bayer Cropscience Limited's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Bayer Cropscience Limited's OCF/NI ratio of 0.46x in FY2025 indicates cash conversion lagging profits — possible working capital challenges.
In FY 2025, Bayer Cropscience Limited's operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Bayer Cropscience Limited's current ratio of 2.01x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Bayer Cropscience Limited reported a current ratio of 2.01. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Bayer Cropscience Limited's interest coverage ratio of 35.6x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Bayer Cropscience Limited reported an interest coverage ratio of 35.6x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Bayer Cropscience Limited's debt-to-equity ratio of 0.04x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Bayer Cropscience Limited reported a debt-to-equity ratio of 0.04. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Bayer Cropscience Limited's debt increased 123.1% YoY in FY2025 — rising leverage demands close monitoring.
In FY 2025, Bayer Cropscience Limited's total debt increased by 123.1% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Bayer Cropscience Limited's diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 44.94M.
In FY 2025, Bayer Cropscience Limited's diluted shares remained flat by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025